AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 12 min read$ALKS

Hopkinson Craig C. sold $375K of ALKS

Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares of Alkermes plc. (ALKS) at $41.67 ($0.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hopkinson Craig C.
Published Jun 1, 2026, 11:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

Absent any accompanying company-specific news (earnings, trial results, approvals, deals, litigation), the disclosure mainly informs positioning/sentiment rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific Form 4 alone is unlikely to drive a durable repricing.

03

What to watch

10b5-1 plans are pre-scheduled and often driven by liquidity/tax planning, reducing the signal-to-noise of insider selling.

Relevance 6/10Novelty 2/10Timing: Filed same day (2026-06-01) as the sale; potential intraday sentiment check.

Background

The filing is an SEC Form 4 for an Alkermes executive (EVP R&D, Chief Medical Officer) reporting an open-market sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Alkermes (ALKS) disclosed an officer open-market sale: 9,000 shares sold on 2026-06-01 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited and quickly mean-reverting.

Evidence & confidence

Form 4 insider sales under a pre-arranged 10b5-1 plan typically have limited informational content versus buys tied to new events.

Market effects

Sector

Minimal; single-company insider transaction without accompanying guidance/clinical/regulatory updates.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the sale volume is unusually large relative to prior patterns, traders could briefly interpret it as caution—even with a 10b5-1 plan.

Key entities

  • issuer
    Alkermes plc

    Subject of the insider transaction disclosure (Form 4) reporting an officer sale of ALKS shares.

  • insider
    Hopkinson Craig C.

    EVP R&D and Chief Medical Officer who sold 9,000 shares on 2026-06-01 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALKS insider trading history →

Related articles

SEP 26
$ALKSLowAI 8/10

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

insidermonkey.com2 min
SEP 24
$ALKSMed

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

investing.com2 min
SEP 22
$ALKSMedAI 8/10

Novel First-in-Class Drug Promising in Early ADHD Study

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.

medscape.com3 min
SEP 21
$ALKSMedAI 8/10

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

Alkermes (ALKS) reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. ALKS 7290 targets the orexin 2 receptor, offering a novel approach to ADHD. The company is enrolling patients for a Phase 2 study. ALKS shares rose 1.27% to $43.95 on Monday.

benzinga.com2 min